-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $67

Benzinga·07/21/2026 12:40:07
Listen to the news
Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $59 to $67.